Advances in biomarker sciences and technology最新文献

{"title":"In vivo multi-omics evaluation of ellagic Acid–Gold nanoparticles from Syzygium cumini for glycemic improvement and β-cell preservation in type 2 diabetic mice","authors":"Muhammad Waqas ,&nbsp;Hafiz Muhammad Javed ,&nbsp;Muhammad Faisal Khan ,&nbsp;Iqra Batool ,&nbsp;Tehmina Saddique ,&nbsp;Khadija Munir ,&nbsp;Razia Bashir","doi":"10.1016/j.abst.2026.01.007","DOIUrl":"10.1016/j.abst.2026.01.007","url":null,"abstract":"<div><div>Diabetes mellitus remains a major global health challenge, affecting over 537 million adults worldwide and this number is expected to rise 783 million by 2045, underscoring the need for improved therapeutic strategies. In this study, we synthesized and evaluated ellagic-acid-loaded gold nanoparticles (EA-AuNPs) prepared from <em>Syzygium cumini</em> seed extract as a potential antidiabetic intervention. EA-AuNPs exhibited a spherical morphology with an average size of 68.4 ± 5.2 nm, zeta potential of −24.6 mV, and encapsulation efficiency of 81.3 ± 2.7 %, indicating stability and optimal drug-loading capacity. In vivo testing in streptozotocin-induced diabetic mice (n = 40) revealed that EA-AuNPs (25 mg/kg, orally, for 28 days) reduced fasting blood glucose by 68.3 % (p &lt; 0.001) and HbA1c by 43.5 % (p &lt; 0.01), while enhancing serum insulin by 2.8-fold. Histological assessment showed restoration of islet morphology with an increase in β-cell area, consistent with protective and recovery-associated effects. Multi-omics analyses supported modulation of metabolic and inflammatory pathways, including PI3K/AKT, AMPK, and NF-κB, consistent with improved glucose homeostasis and reduced oxidative stress (MDA ↓52.4 %, SOD ↑2.1-fold). Collectively, these findings suggest that EA-AuNPs may offer a promising nanophytochemical approach for managing Type 2 diabetes, warranting further mechanistic and translational investigation.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 236-253"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging biomarkers of the tumour microenvironment: Advances in early cancer detection and treatment response monitoring","authors":"Aswini Rajendran,&nbsp;Sowmiya Philip,&nbsp;Veronica Elumalai,&nbsp;Sudharshini Srinivasan,&nbsp;Karthikeyan Elumalai","doi":"10.1016/j.abst.2026.01.006","DOIUrl":"10.1016/j.abst.2026.01.006","url":null,"abstract":"<div><div>Molecular imaging of the tumor microenvironment (TME) is an excellent method for identifying cancer at an early stage and monitoring treatment progress. Emerging techniques, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and optical and photoacoustic imaging, allow the examination of large portions of the TME without necessarily incising them. These include low oxygen levels, new blood vessel formation, immunocyte infiltration, alterations in the extracellular matrix, and changes in body energy consumption. The development of new radiotracers, activatable probes, and multimodal nanoparticles has simplified the process of viewing the TME at a higher level and displaying more than one thing at a time. TME imaging aids clinicians in identifying aggressive malignancies at an earlier stage and displays changes in molecules and functions prior to the emergence of structural alterations that are easy to observe. This simplifies the identification and prioritization of risks, thereby accelerating treatment initiation. If doctors can discover TME features without surgery, they can also tailor treatments to each individual, observe the progress of treatments early, and modify treatments based on the behavior of each tumor. In particular, it is difficult to normalize imaging methods, demonstrate that new probes can be used in clinical settings, and relate molecular imaging data to data from other omics platforms. Therefore, the design of finer and more valid probes is required. Multicentre clinical trials are needed to determine the ability of TME imaging biomarkers to predict outcomes. Finally, we would like AI to create models that will assist us in examining photographs and making better conjectures. There is a continual improvement in molecular imaging tools. They would be able to change the way cancer is managed by simplifying the process of early stage detection, tailoring treatment to an individual, and improving their lives.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 254-268"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential of IP-10 and sCD14 as inflammatory biomarkers in HIV–TB co-infection: a systematic review","authors":"Tolutope Adebimpe Oso ,&nbsp;Olalekan John Okesanya ,&nbsp;Uthman Okikiola Adebayo ,&nbsp;Khalifat Boluwatife Obadeyi ,&nbsp;Oluwatobi Babajide Ayelaagbe ,&nbsp;Mohamed Mustaf Ahmed ,&nbsp;Clement Ngele Chukwu ,&nbsp;Olaoluwa Joseph Oso ,&nbsp;Don Eliseo Lucero-Prisno III","doi":"10.1016/j.abst.2025.12.001","DOIUrl":"10.1016/j.abst.2025.12.001","url":null,"abstract":"<div><h3>Background</h3><div>Human Immunodeficiency Virus (HIV) and tuberculosis (TB) are major global health challenges, especially in sub-Saharan Africa and Southeast Asia, where their co-infection greatly increases illness and death. People living with HIV are far more likely to develop TB, and the interaction between the two infections worsens immune dysfunction and complicates management.</div></div><div><h3>Methods</h3><div>This systematic review followed PRISMA 2020 guidelines to assess the roles of Interferon-γ–induced Protein 10 (IP-10) and Soluble Cluster of Differentiation 14 (sCD14) as inflammatory biomarkers in HIV-TB co-infection. A comprehensive search of PubMed, Scopus, and Google Scholar was conducted for studies published between 2014 and 2024. Eligible interventional and observational studies involving adults with HIV-TB co-infection were included based on predefined inclusion criteria. Data extraction covered study characteristics, biomarker levels, and their associations with inflammation, disease progression, and clinical outcomes.</div></div><div><h3>Results</h3><div>Six studies met the inclusion criteria, all assessing IP-10, while only one measured sCD14. Most studies reported significantly elevated IP-10 levels in HIV–TB co-infected individuals, linking it to systemic inflammation, disease progression, and poor clinical outcomes, highlighting its potential as a predictive and prognostic biomarker. The single study evaluating sCD14 found increased levels indicating generalized immune activation but limited specificity for distinguishing Tuberculosis-Immune Reconstitution Inflammatory Syndrome , suggesting its broader role as a nonspecific marker of inflammation.</div></div><div><h3>Conclusion</h3><div>Although the current evidence base is limited, IP-10 shows promise as a diagnostic and prognostic biomarker, and sCD14 may complement its use as a marker of immune activation. Further large-scale, standardized studies are needed to validate these biomarkers in HIV–TB co-infection.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 44-54"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker-guided precision immunotherapy in head and neck cancer: Harnessing toripalimab-tpzi as a PD-1 checkpoint inhibitor","authors":"Kaviyashri Ramesh,&nbsp;Sudharshini Srinivasan,&nbsp;Sharmila Sakthisivanandhan,&nbsp;Dhanush Periyasamy,&nbsp;Sree Ram Sivakumar,&nbsp;Praveenkumar Ramesh,&nbsp;Karthikeyan Elumalai","doi":"10.1016/j.abst.2026.01.010","DOIUrl":"10.1016/j.abst.2026.01.010","url":null,"abstract":"<div><div>The recent humanized anti-programmed death-1 (PD-1) monoclonal antibody, toripalimab-tpzi, has now become a promising immunotherapeutic agent in the control of head and neck cancer (HNC), especially head and neck squamous cell carcinoma (HNSCC), the most common form of the disease, constituting approximately 90 % of all cases. In this conceptual review, the authors critically examine the molecular processes, clinical activity, safety, biomarker-guided precision of their approach, resistance biology, and combination regimens of toripalimab-tpzi in HNSCC. Toripalimab-tpzi offers antitumor effects due to selective inhibition restricting the PD-1/programmed death-ligand 1 (PD-L1) axis, which restores cytotoxic T-cell activity and intensifies the antitumor immune responses. In the Phase I-III clinical trials on recurrent or metastatic HNSCC, the objective response rates of toripalimab-tpzi were around 20-36, the median progression-free survival (PFS) was 2.8–4.5 months, and the median overall survival was 10–15 months, especially with PD-L1-enriched populations. The safety profile is comparable to the PD-1 class effects, and the majority of the immune-related adverse events (irAEs) were grade 1-2 and grade 3-4 toxicities that were rare in less than 20 percent of the patients. The new evidence is pointing to the significance of patient selection according to biomarker to maximize therapeutic response. The single predictive utility of such markers as PD-L1 expression, tumor mutational burden, microsatellite instability, tumor-infiltrating lymphocytes, or immune gene signatures is variable, with the deficiency of single-biomarker systems. Integration therapy involving toripalimab-tpzi and platinum-based chemotherapy, radiotherapy, targeted therapies, or other immunomodulators has been shown to result in better response rates (up to 4060 % in select studies) and may result in resistance being overcome by intrinsic or acquired immunomodulatory mechanisms. Unlike previous generalized scientific reviews of PD-1/PD-L1 blocking in HNSCC, the article summarizes the toripalimab-tpzi-specific clinical and translational data and suggests a precautionary immunotherapy paradigm and a biomarker-driven combination-resistance management plan. Taken together, the above data favor toripalimab-tpzi as a clinically significant supplement to precision immunotherapy in HNSCC, whose optimal role is determined by the biologically informed selection of patients and the rational combination of multimodal treatment.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 269-291"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The integration of artificial intelligence and biotechnology in medicine: accelerating novelty in biomarker-targeted discovery and drug delivery systems","authors":"Christopher Busayo Olowosoke ,&nbsp;Daniel Ogbonnaya Nwankwo ,&nbsp;Chinedu Shedrach Izu ,&nbsp;Prosper Obed Chukwuemeka","doi":"10.1016/j.abst.2025.12.002","DOIUrl":"10.1016/j.abst.2025.12.002","url":null,"abstract":"<div><div>Artificial intelligence (AI) and biotechnology are two transformative fields converging to benefit STEM because of their reliance on data and models. The tools from both fields have redefined and improved translational performance of laboratory investigations on drug and biomarker-targeted discovery, drug design, drug development and drug delivery for personalized treatment. Although the long term merit of this integration of AI in biotechnology outweighs the demerit but is the current trend suitable and truly applicable for clinical intervention and therapy upgrades. In this article, we indicated how some key AI-biotech research is supporting accelerated novelty in biomarker-targeted discovery and drug delivery system (DDS) for disease management rather than merely incremental changes in 21st century.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 137-140"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut–kidney axis disruption by antibiotics: Dysbiosis, renal dysfunction and biomarker insights","authors":"Zhao Han ,&nbsp;Bo Yang ,&nbsp;Nanmei Liu ,&nbsp;Cheng Xue","doi":"10.1016/j.abst.2025.12.007","DOIUrl":"10.1016/j.abst.2025.12.007","url":null,"abstract":"","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 134-136"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of withacoagulin from Withania coagulans for glycemic improvement and β-cell preservation in a type 2 diabetic model","authors":"Muhammad Waqas ,&nbsp;Muhammad Umar Farooq ,&nbsp;Tehmina Saddique ,&nbsp;Ali Raza ,&nbsp;Muhammad Tayyab ,&nbsp;Razia Bashir","doi":"10.1016/j.abst.2025.12.008","DOIUrl":"10.1016/j.abst.2025.12.008","url":null,"abstract":"<div><div>Type 2 diabetes mellitus remains a global health emergency, with existing therapies often failing to achieve durable glycemic control or preserve pancreatic β-cell function. In this study, we isolated and purified withacoagulin, a novel withanolide from <em>Withania coagulans</em>, confirmed by NMR, MS, FTIR, and HPLC (&gt;98 % purity). A total of 72 male Wistar rats were randomized into six groups (n = 12 per group): normal control, diabetic control (streptozotocin–nicotinamide), metformin (100 mg/kg), insulin (4 U/kg), and withacoagulin at 10, and 20 mg/kg. Twelve weeks of oral withacoagulin administration resulted in significant improvements in glycemic control, including a 62 % reduction in fasting blood glucose and a 65 % decrease in HbA1c relative to diabetic controls (p &lt; 0.001). These effects were accompanied by marked improvements in insulin sensitivity, evidenced by reduced HOMA-IR and increased QUICKI indices. Histological and immunohistochemical analyses demonstrated preservation of pancreatic islet morphology and enhanced insulin immunoreactivity in treated animals. Dyslipidemia was corrected, oxidative stress markers were improved (↑SOD, ↑CAT, ↑GPx; ↓MDA), and pro-inflammatory cytokines (TNF-α, IL-6) were significantly lowered. Mechanistic analyses demonstrated reactivation of IRS-1/PI3K/Akt signaling, increased GLUT4 translocation, and upregulation of AMPK phosphorylation, highlighting a multi-targeted mechanism of action. A 28-day subacute toxicity study conducted in accordance with OECD guidelines indicated no observable hepatic, renal, hematological, or histopathological abnormalities at doses up to 500 mg/kg, establishing a favorable preliminary safety profile. Collectively, these findings provide support for withacoagulin's potential as a mechanistically active natural lead compound for further preclinical development in metabolic disease research.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 184-198"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant and neuroprotective effects of Launaea taraxacifolia extract against aluminum-induced neurotoxicity","authors":"Idorenyin U. Umoren ,&nbsp;Nnanake-Abasi O. Offiong ,&nbsp;Niibari W. Vite","doi":"10.1016/j.abst.2025.12.010","DOIUrl":"10.1016/j.abst.2025.12.010","url":null,"abstract":"<div><div>This study evaluated the antioxidant and neuroprotective effects of ethanol leaf extract and fractions of <em>Launaea taraxacifolia</em> against aluminum chloride-induced neurotoxicity in rats. Sixty-six female Wistar rats were divided into eleven groups, receiving either control treatment, aluminum chloride, donepezil, or different doses/fractions of the plant extract for 21 days. Aluminum chloride significantly reduced antioxidant enzyme activities (SOD, CAT, GPx) and increased lipid peroxidation (MDA). Co-treatment with the ethanol extract, dichloromethane, ethylacetate, and n-butanol fractions restored antioxidant defenses and reduced MDA levels, whereas the n-hexane and aqueous fractions showed little effect. These findings indicate that <em>Launaea taraxacifolia</em> contains bioactive compounds with protective effects against oxidative stress and neuronal injury, supporting its potential as a natural neuroprotective agent.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 141-150"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping autophagy-lncRNA co-expression networks in early ovarian carcinoma by stage-resolved transcriptomic modelling","authors":"A. Shriraksha,&nbsp;V.R. Devaraj","doi":"10.1016/j.abst.2025.12.003","DOIUrl":"10.1016/j.abst.2025.12.003","url":null,"abstract":"<div><div>Early-stage ovarian carcinoma exhibits heterogeneous molecular programming that influences tumor progression and therapeutic vulnerability. Using RNA-seq data from 96 tumors (GSE101108), we developed an integrative bioinformatics workflow that combines DESeq2, ssGSEA, and weighted gene co-expression network analysis (WGCNA) to identify autophagy-associated biomarkers and long non-coding RNA (lncRNA)- driven co-expression networks across FIGO stage I-II ovarian tumors. Differential expression analysis (DESeq2) identified 140 stage-dependent genes, with the lncRNA LOC105374020 emerging as the most upregulated transcript in FIGO II tumors. ssGSEA revealed elevated autophagy activity in FIGO II tumors, coinciding with the enrichment of MHC class I antigen-processing pathways, suggesting adaptive remodeling of immune surveillance. WGCNA uncovered a lncRNA-enriched module strongly correlating with autophagy intensity (r = 0.78, FDR = 1.8 × 10⁻¹⁹). Within this module, LOC105374020 displayed high intramodular connectivity, making it a potential regulator of early tumor adaptation. These results suggest lncRNAs embedded within autophagy-linked modules as candidate biomarkers of early progression and immune modulation. Collectively, this study outlines a systems-level framework integrating autophagy, immunity, and lncRNA regulation in early ovarian carcinoma. While the findings highlight promising biomarker candidates, additional external validation and functional assays will be essential to translate these signatures for prognostic or therapeutic use.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 55-66"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico screening of tripeptide inhibitors reveals potential lead compounds for targeting zika virus NS2B-NS3 protease","authors":"Farhan Ullah ,&nbsp;Wajeeha Rahman ,&nbsp;Anees Ullah ,&nbsp;Shahid Ullah ,&nbsp;Sheng Wang","doi":"10.1016/j.abst.2025.11.001","DOIUrl":"10.1016/j.abst.2025.11.001","url":null,"abstract":"<div><div>ZIKV is a public health threat causing neurological complications such as microcephaly and Guillain-Barre syndrome, with the additional risk of sexual transmission. The absence of FDA-approved drugs or vaccines for ZIKV, highlight the immediate requirement for potential therapeutics. A potential target for antiviral drug development is the NS2B-NS3 protease which is a critical enzyme in the replication and maturation of ZIKV. Here, we report the inhibitory activity of tripeptide compounds for this protease via molecular docking and molecular dynamics (MD) study. The docking studies were further followed by a 200 ns MD simulation to investigate the stability and binding mode of the inhibitor within the active site of protease. The simulation revealed that, the complex remains stable with lower root mean square deviation RMSD and higher root mean square fluctuation (RMSF) values and showed strong ligand-protein interaction. Further investigation of torsion angles in the ligand and secondary structural changes in the protease support to the viability of these tripeptide inhibitors as anti-viral agents. The results obtained in this study suggest that tripeptide-derived inhibitors of ZIKV may be applied as potential leads for developing novel therapies against the ZIKV, indicating a potential direction for future drug discovery and clinical treatments.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"8 ","pages":"Pages 34-43"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}